Avalyn Pharma Inc. (Nasdaq: AVLN) has filed to raise approximately $200 million in its upcoming IPO, offering 11.8 million shares at a price range of $16 to $18, implying a midpoint deal size of roughly $200.6 million. At the midpoint price of $17, the company is expected to command a market capitalization of approximately $628 million based on 36.9 million shares outstanding post-offering. The deal is being led by Morgan Stanley, Jefferies, Evercore ISI, and Guggenheim Securities, with shares expected to list on the Nasdaq Global Market under the ticker AVLN.
Avalyn is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious, rare respiratory diseases, with an initial focus on pulmonary fibrosis. The company’s core strategy centers on reformulating existing oral antifibrotic drugs—specifically pirfenidone and nintedanib—into inhaled versions designed to deliver drug directly to the lungs. This approach aims to increase efficacy at the site of disease while reducing systemic exposure, which is a key limitation of current oral therapies.
Pulmonary fibrosis represents a significant unmet need, with a median survival of just three to five years and limited treatment options. While existing therapies such as Esbriet and Ofev generate over $4 billion in global sales annually, their use is constrained by tolerability issues, with approximately 50% of patients discontinuing treatment within one year. Avalyn’s inhaled approach is designed to address this gap by improving the benefit-risk profile and enabling longer-term treatment adherence.
The company’s pipeline is led by AP01 (inhaled pirfenidone) and AP02 (inhaled nintedanib), both currently in mid-stage development. AP01 is being evaluated in the Phase 2b MIST trial for progressive pulmonary fibrosis, supported by earlier data showing favorable tolerability and signs of lung function stabilization. AP02 is in a Phase 2 trial (AURA) for idiopathic pulmonary fibrosis, with early data demonstrating targeted lung delivery and reduced systemic exposure. Avalyn is also advancing AP03, a fixed-dose combination of both drugs, designed to deliver dual antifibrotic mechanisms through a single inhaled therapy—potentially unlocking combination benefits without the toxicity seen in oral regimens.
A key differentiator in Avalyn’s platform is its exclusive licensing agreement with PARI’s eFlow nebulizer technology, which is already clinically validated across multiple approved therapies. This drug-device combination strategy not only supports targeted delivery but also creates potential regulatory and commercial barriers to entry, as the device is expected to be included in any approved product labeling.
Financially, Avalyn reflects a typical clinical-stage biotech profile, with no revenue and increasing R&D investment. The company reported a net loss of $85.2 million in 2025, up from $49.7 million in 2024, and an accumulated deficit of $265.4 million. Proceeds from the IPO are expected to fund continued development of AP01 and AP02, as well as advancement of AP03 and broader pipeline expansion, with runway projected into 2029.
From a competitive standpoint, Avalyn enters a space dominated by large-cap pharmaceutical players but differentiated by delivery mechanism rather than new molecular entities. Comparable public biotech IPOs in the respiratory and rare disease space have seen mixed reception, with investor focus increasingly centered on clinical data visibility, differentiation, and capital efficiency. Avalyn’s inhaled reformulation strategy may resonate as a lower-risk, mechanism-validated approach, though ultimate success will hinge on clinical outcomes and regulatory acceptance of inhaled endpoints.
Overall, Avalyn represents a platform-driven biotech story targeting a well-established market with clear unmet needs, positioning itself at the intersection of drug reformulation and delivery innovation. With multiple mid-stage catalysts expected over the next 18–24 months, the IPO will test investor appetite for differentiated clinical strategies within the broader reopening biotech issuance window.
AVLN is expected to price Wednesday, April 29th and trade Thursday, April 30th.